JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

141 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank -2-

24. Apr. 2026, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Group Rejects EQT's Revised Offer

26. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. Apr. 2026, 23:36 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Falls Amid Dollar's Strength -- Market Talk

26. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. Apr. 2026, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Scoring the Cook Era -- Barrons.com

24. Apr. 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:09 UTC

Ergebnisse

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. Apr. 2026, 19:48 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. Apr. 2026, 19:22 UTC

Ergebnisse

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. Apr. 2026, 19:06 UTC

Ergebnisse

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. Apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. Apr. 2026, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. Apr. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Rejects Revised EQT Offer

24. Apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. Apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. Apr. 2026, 17:42 UTC

Ergebnisse

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Ergebnisse

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

141 / 348 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.